

Katherine A B Kellett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3737164/publications.pdf>

Version: 2024-02-01

21
papers

1,045
citations

516561

16
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

2226
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease. ACS Nano, 2021, 15, 7357-7369.	7.3	17
2	3D hydrogel models of the neurovascular unit to investigate blood-brain barrier dysfunction. Neuronal Signaling, 2021, 5, NS20210027.	1.7	20
3	Proteolysis of the low density lipoprotein receptor by bone morphogenetic protein-1 regulates cellular cholesterol uptake. Scientific Reports, 2019, 9, 11416.	1.6	13
4	Quantitative interaction proteomics reveals differences in the interactomes of amyloid precursor protein isoforms. Journal of Neurochemistry, 2019, 149, 399-412.	2.1	12
5	Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid- β oligomers. Journal of Biological Chemistry, 2019, 294, 7085-7097.	1.6	38
6	Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. Journal of Alzheimer's Disease, 2018, 63, 13-33.	1.2	111
7	Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia?. Neurochemistry International, 2018, 118, 134-144.	1.9	39
8	Plasma metals as potential biomarkers in dementia: a case-control study in patients with sporadic Alzheimer's disease. BioMetals, 2018, 31, 267-276.	1.8	13
9	Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells. Neurochemical Research, 2018, 43, 2179-2198.	1.6	27
10	Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia. Scientific Reports, 2016, 6, 27524.	1.6	68
11	A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. Journal of Biological Chemistry, 2016, 291, 19235-19244.	1.6	151
12	Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- β or Pathologic Phenotype. PLoS ONE, 2016, 11, e0159119.	1.1	9
13	The Role of Tissue Non-specific Alkaline Phosphatase (TNAP) in Neurodegenerative Diseases: Alzheimer's Disease in the Focus. Sub-Cellular Biochemistry, 2015, 76, 363-374.	1.0	18
14	Discovery of Biphenylacetamide-Derived Inhibitors of BACE1 Using de Novo Structure-Based Molecular Design. Journal of Medicinal Chemistry, 2013, 56, 1843-1852.	2.9	16
15	Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid- β Levels and Braak Stage. PLoS ONE, 2013, 8, e59554.	1.1	35
16	BIN1 Is Decreased in Sporadic but Not Familial Alzheimer's Disease or in Aging. PLoS ONE, 2013, 8, e78806.	1.1	65
17	Alkaline Phosphatase Is Increased in both Brain and Plasma in Alzheimer's Disease. Neurodegenerative Diseases, 2012, 9, 31-37.	0.8	71
18	Prion Protein Interacts with BACE1 Protein and Differentially Regulates Its Activity toward Wild Type and Swedish Mutant Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 33489-33500.	1.6	53

#	ARTICLE	IF	CITATIONS
19	The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain Is Preferentially Produced from the 695 Isoform of APP in a β -Secretase-dependent Pathway. <i>Journal of Biological Chemistry</i> , 2010, 285, 41443-41454.	1.6	175
20	Prion protein and Alzheimer disease. <i>Prion</i> , 2009, 3, 190-194.	0.9	66
21	Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6770-6774.	1.0	28